|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.15 USD | -0.39% |
|
+4.15% | -22.21% |
| Apr. 15 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
| Mar. 22 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
TELA Bio, Inc. provided revenue guidance for the fiscal year 2022. The company delivering on its revenue guidance of USD 40 million to USD 45 million in the calendar year 2022.
| 1st Jan change | Capi. | |
|---|---|---|
| -22.21% | 127M | |
| -4.36% | 183B | |
| -3.87% | 105B | |
| -4.38% | 67.36B | |
| +8.23% | 51.77B | |
| +15.54% | 47.29B | |
| -1.73% | 40.2B | |
| +7.16% | 27.62B | |
| -16.62% | 21.75B | |
| -1.68% | 25.51B |
TELA BIO, INC. 
